首页> 美国卫生研究院文献>Sleep >Practice Parameters for the Treatment of Narcolepsy and other Hypersomnias of Central Origin An American Academy of Sleep Medicine Report
【2h】

Practice Parameters for the Treatment of Narcolepsy and other Hypersomnias of Central Origin An American Academy of Sleep Medicine Report

机译:治疗发作性睡病和其他中枢性过高睡眠的实践参数美国睡眠医学研究院报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

These practice parameters pertain to the treatment of hypersomnias of central origin. They serve as both an update of previous practice parameters for the therapy of narcolepsy and as the first practice parameters to address treatment of other hypersomnias of central origin. They are based on evidence analyzed in the accompanying review paper. The specific disorders addressed by these parameters are narcolepsy (with cataplexy, without cataplexy, due to medical condition and unspecified), idiopathic hypersomnia (with long sleep time and without long sleep time), recurrent hypersomnia and hypersomnia due to medical condition. Successful treatment of hypersomnia of central origin requires an accurate diagnosis, individual tailoring of therapy to produce the fullest possible return of normal function, and regular follow-up to monitor response to treatment. Modafinil, sodium oxybate, amphetamine, methamphetamine, dextroamphetamine, methylphenidate, and selegiline are effective treatments for excessive sleepiness associated with narcolepsy, while tricyclic antidepressants and fluoxetine are effective treatments for cataplexy, sleep paralysis, and hypnagogic hallucinations; but the quality of published clinical evidence supporting them varies. Scheduled naps can be beneficial to combat sleepiness in narcolepsy patients. Based on available evidence, modafinil is an effective therapy for sleepiness due to idiopathic hypersomnia, Parkinson's disease, myotonic dystrophy, and multiple sclerosis. Based on evidence and/or long history of use in the therapy of narcolepsy committee consensus was that modafinil, amphetamine, methamphetamine, dextroamphetamine, and methylphenidate are reasonable options for the therapy of hypersomnias of central origin.Citation:Morgenthaler TI; Kapur VK; Brown T; Swick TJ; Alessi C; Aurora RN; Boehlecke B; Chesson AL; Friedman L; Maganti R; Owens J; Pancer J; Zak R; Standards of Practice Committee of the AASM. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. SLEEP 2007;30(12):1705-1711.
机译:这些实践参数涉及中枢性高睡眠血症的治疗。它们既是对发作性睡病治疗的先前实践参数的更新,又是解决其他中枢性失眠症治疗的第一个实践参数。它们基于随附评论文件中分析的证据。这些参数所针对的特定疾病是发作性睡病(由于医疗条件而未分类,有昏厥,无昏厥),特发性失眠(睡眠时间长且睡眠时间不长),反复发作的失眠和由于医学状况引起的失眠。成功治疗中枢性失眠症需要准确的诊断,对疗法进行个体化调整以使正常功能得到最大可能的恢复,并定期随访以监测对治疗的反应。莫达非尼,羟丁酸钠,苯丙胺,甲基苯丙胺,右旋苯丙胺,哌醋甲酯和司来吉兰是有效的治疗与嗜睡症有关的过度嗜睡的方法,而三环类抗抑郁药和氟西汀是对瘫痪,睡眠麻痹和催眠幻觉有效的治疗方法;但是支持它们的已发表临床证据的质量各不相同。计划的小睡可以有助于缓解发作性睡病患者的嗜睡。根据现有证据,莫达非尼是特发性失眠症,帕金森氏病,肌强直性营养不良和多发性硬化症引起的嗜睡的有效疗法。基于对发作性睡病委员会治疗的证据和/或悠久的使用历史,共识是莫达非尼,苯丙胺,甲基苯丙胺,右旋苯丙胺和哌醋甲酯是治疗中枢性高睡眠血症的合理选择。卡普尔VK;棕色T; Swick TJ; Alessi C;极光RN; Boehlecke B; Chesson AL;弗里德曼Maganti R;欧文斯J; Pancer J; Zak R; AASM的实践标准委员会。治疗发作性睡病和其他中枢性失眠的实践参数。睡眠2007; 30(12):1705-1711。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号